Six monoclonal antibodies (mAb) were produced by immunizing mice with a Cryptococcus neoformans serotype A spheroplast lysate (CNSL). Two mAb were of the IgG1 isotype; the others were IgM. The results obtained with one IgM mAb (CN6) are reported herein. This mAb recognized the four serotypes of C. neoformans and no cross-reactions were observed with extracts from Cryptococcus melibiosum, Candida albicans, Saccharomyces cerevisiae, Torulopsis glabrata or Trichosporon beigelii. Fractionation of the CNSL by gel filtration revealed that mAb CN6 recognized high molecular weight substances as well as a range of smaller molecules. Indirect ELISA inhibition studies showed that this mAb recognized substances in a cryptococcal culture filtrate. Inhibition studies and agglutination tests using latex beads sensitized with purified CN6 showed that CN6 strongly reacted with the C. neoformans serotype A cell envelope galactoxylomannan-mannoprotein complex (GAlXM-MP) and only weakly with the glucuronoxylomannan (GXM) component. These tests also showed that purified galactoxylomannan (GalXM) from C. neoformans serotype A was more reactive than purified mannoprotein (MP). An anti-GalXM mAb might be a useful tool for monitoring the clinical course of cryptococcal infections.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0923-2494(90)90099-k | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Screening for cryptococcal antigenemia and meningeal cryptococcosis, genetic characterization of Cryptococcus neoformans in asymptomatic patients with advanced HIV disease in Kinshasa, Democratic Republic of Congo.
Sci Rep
December 2024
Clinical Microbiology Laboratory, National Reference Center for Mycosis, Center for Interdisciplinary Research on Medicines (CIRM), University of Liege, Liege, Belgium.
We evaluated the prevalence of serum and meningeal cryptococcosis in asymptomatic outpatients with advanced HIV disease (CD4 < 200 cells/mm3) in a cross-sectional screening context in Kinshasa clinics (DRC). Lumbar puncture (LP) was performed in patients with positive serum cryptococcal antigen (CrAg) test, and Cryptococcus spp. isolated from cerebrospinal fluid (CSF) were identified by MALDI-TOF-MS, and characterized using serotyping-PCR, ITS-sequencing and multilocus sequence typing (MLST).
View Article and Find Full Text PDFA case of primary cutaneous Cryptococcus neoformans infection.
BMC Infect Dis
August 2024
Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zhejiang, China.
Article Synopsis
- Cryptococcosis is an infection caused by a type of yeast, primarily affecting those with weakened immune systems, though cases involving skin infections are rare.
- A 61-year-old woman with rheumatoid arthritis experienced a worsening skin lesion that was initially misdiagnosed, but tests ultimately identified it as a cutaneous infection from Cryptococcus neoformans, confirmed through microbiological and histopathological analysis.
- Treatment with oral fluconazole led to significant improvement of the infection, highlighting the need to consider primary cutaneous cryptococcosis in patients with skin ulcers resistant to standard antibiotics.
Broad Protection against Invasive Fungal Disease from a Nanobody Targeting the Active Site of Fungal β-1,3-Glucanosyltransferases.
Angew Chem Int Ed Engl
August 2024
Institute of Biocomputation and Physics of Complex Systems (BIFI), University of Zaragoza, Mariano Esquillor s/n, Campus Rio Ebro, Edificio I+D, 50018, Zaragoza, Spain.
Article Synopsis
- * Researchers used single-domain nanobodies from camels to target a specific enzyme (β-1,3-glucanosyltransferases) crucial for fungal survival, revealing important structural insights.
- * The tested nanobody showed strong antifungal effects in laboratory settings and in animal models, particularly against certain strains of C. neoformans, suggesting it could be a promising avenue for developing new antifungal therapies.
Phenotypic characterization of , a novel mating regulator of the fungal pathogen .
Microbiol Spectr
July 2024
Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, USA.
Unlabelled: is a fungal pathogen responsible for >200,000 yearly cases with a mortality as high as 81%. This burden results, in part, from an incomplete understanding of its pathogenesis and ineffective antifungal treatments; hence, there is a pressing need to understand the biology and host interactions of this yeast to develop improved treatments. Protein palmitoylation is important for cryptococcal virulence, and we previously identified the substrates of its main palmitoyl transferase.
View Article and Find Full Text PDFSemisynthetic Glycoconjugate Vaccine Candidates against .
ACS Infect Dis
June 2024
Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore 21205, Maryland, United States.
Article Synopsis
- A study highlights the development of two semisynthetic vaccine candidates targeting a fungus that poses serious risks to immunocompromised patients, focusing on its key polysaccharide, glucuronoxylomannan (GXM).
- The vaccines, containing a synthetic decasaccharide antigen (M2 motif), were conjugated to two proteins and tested in mice, showing specific immune responses and some cross-reactivity to other GXM variants.
- While one glycoconjugate showed potential for increased survival in mice, further optimizations are needed before it can be considered for a multivalent GXM vaccine.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!